References in periodicals archive ?
This compelling human research crowns a series of studies indicating that undenatured type II cartilage induces oral tolerance to exposed collagen, inhibiting the immune response that inflames joints and further degrades joint cartilage.
Specific oral tolerance induction (SOTI) is a promising new therapy for IgE-mediated CMA.
In the present study, we speculate that two factors, namely low dose of antigen loading and modified peptides, induce active suppression and produce a blocking antibody, resulting in oral tolerance.
Molecular analysis also revealed clues to explain how oral tolerance therapy might dampen the allergic response.
So far so good, except that Weiner has hardly a clue how oral tolerance actually works, or at least Quinn fails to explain it adequately, leaving the reader to wonder whether this is just some cockamamie idea cooked up by a bright, but overeager doctor and then marketed ferociously to Wall Street.
Optiquel[TM] therapy is based on oral tolerance, an immunologic mechanism that down-regulates immune responses in an antigen-specific manner, rather than a non-specific immunosuppressive approach.
The efficacy seen with the lowest dosage is consistent with the findings of animal studies and with known mechanisms of oral tolerance in which lower doses of orally administered autoantigens preferentially induce disease-suppressing regulatory cells.
Proceedings of an October 2003 conference held in New York City, synthesizing the large number of advances that have been made in understanding mechanisms of oral tolerance in animal models over the past decade and their applications to the treatment of human disease.
Conceptually, the phenomenon of oral tolerance is well established experimentally, and at least some of the important immunologic mechanisms have been described (Brandtzaeg 1996; Mowat 1987; Strobel 1997; Strobel and Mowat 1998).
But Weiner hasn't given up on the concept of oral tolerance.
Although reminiscent of 19th-century snake oil medicine, oral tolerance therapy--persuading a person's body to accept foreign proteins by feeding those proteins to the person--may offer a specific, extremely safe way to treat a host of autoimmune diseases.
arGentis researchers believe that the SNP maker may be applicable to achieving oral immune tolerance in many, if not all, autoimmune diseases, providing a platform for developing oral tolerance therapeutics for large subpopulations of those diseases.